Predicted protein targets (top 6)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CRBN | Q96SW2 | 18/20 | 0.91 |
| ▸ | IKZF3 | Q9UKT9 | 18/20 | 0.91 |
| ▸ | TNF | P01375 | 3/20 | 0.88 |
| ▸ | IL1B | P01584 | 3/20 | 0.88 |
| ▸ | IKZF1 | Q13422 | 1/20 | 0.88 |
| ▸ | DDB1 | Q16531 | 1/20 | 0.88 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL26321494 | 1.00 | CRBN (0.91) | CRBNIKZF3TNFIL1BIKZF1 | |
| SCHEMBL22243504 | 0.97 | CRBN (0.89) | CRBNIKZF3TNFIL1BIKZF1 | |
| SCHEMBL21939263 | 0.96 | CRBN (0.85) | CRBNIKZF3TNFIL1BIKZF1 | |
| SCHEMBL2252296 | 0.96 | CRBN (0.91) | CRBNIKZF3TNFIL1BIKZF1 | |
| SCHEMBL2252158 | 0.96 | CRBN (0.85) | CRBNIKZF3TNFIL1BIKZF1 | |
| SCHEMBL24146212 | 0.96 | CRBN (0.87) | CRBNIKZF3TNFIL1BIKZF1 | |
| SCHEMBL2249787 | 0.96 | CRBN (1.00) | CRBNIKZF3TNFIL1BIKZF1 | |
| SCHEMBL2249312 | 0.95 | CRBN (0.84) | CRBNIKZF3TNFIL1BIKZF1 | |
| SCHEMBL2248944 | 0.95 | CRBN (0.83) | CRBNIKZF3TNFIL1BIKZF1 | |
| SCHEMBL2252489 | 0.95 | CRBN (0.85) | CRBNIKZF3TNFIL1BIKZF1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-11730726-B2 | Dimeric immuno-modulatory compounds against cereblon-based mechanisms | H. LEE MOFFITT CANCER CENTER AND RESEARCH INSTITUTE, INC. (US) | 2023-08-22 | — | — | US | disclosed |
| US-11730726-B2 | Dimeric immuno-modulatory compounds against cereblon-based mechanisms | H. LEE MOFFITT CANCER CENTER AND RESEARCH INSTITUTE, INC. (US) | 2023-08-22 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-11730726-B2 | Dimeric immuno-modulatory compounds against cereblon-based mechanisms | CRBN, CD4, CD74 | CRBN 1/4885IKZF3 327/4885TNF 3516/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.